Avalon Pharma
أفالون فارماTechnical Analysis & Signals
Avalon Pharma closed at SAR 67.2, up 1.82%. RSI at 65.0 in neutral zone. Current signal: Buy.
Technical Analysis
Avalon Pharma closed at SAR 67.2, above the 50-day SMA (63.18 SAR). RSI at 65.0 (neutral). MACD shows bullish momentum with histogram at 0.6837. Bollinger range: 56.61 – 67.14 SAR.
Support & Resistance Levels
Key support at SAR 55.6. Resistance at SAR 68.4. A break below support could push the stock toward SAR 53.93, while a breakout above resistance opens the path to SAR 70.45.
Volume Analysis
Session volume 235,658 shares is above the 30-day average (78,394 shares). Higher volume with price movement supports the current trend.
Fundamental Factors
P/E ratio at 27.8x. Dividend yield around 2.0%. Market cap SAR 2,352,000,000.0.
Risk Factors
Technical indicators sit in neutral territory (RSI 65, debt-to-equity 0.4114).
Recommendation
Based on current technical and fundamental data for Avalon Pharma. Monitor support at SAR 55.6 and resistance at SAR 68.4 for entry and exit points.
Financial Fundamentals
Price Data
Price Chart - Avalon Pharma
4016Technical Analysis
Moving Averages
Momentum Indicators
Bollinger Bands
Above Upper BandTrend Strength (ADX)
Weak TrendFinancial Summary
Valuation
- Market Cap
- 2.35B
- P/E Ratio
- 27.80
- P/B Ratio
- 5.40
- EPS (Earnings/Share)
- 2.42
Profitability
- Revenue
- 528.49M
- Net Income
- 115.66M
- Return on Equity (ROE)
- +28.70%
- Shares Outstanding
- 35.00M
Balance Sheet
- Total Assets
- 599.53M
- Total Debt
- 178.82M
- Debt/Equity
- 0.41
- Free Float %
- +47.0%
Dividends & Margins
- Dividend Yield
- +2.36%
- Dividend/Share
- 1.55
- Book Value
- 12.44
Financial data extracted from published quarterly reports. All values in SAR unless otherwise stated.
Historical Financial Data
3 years| Year | Revenue | Net Income | Total Assets | Total Debt | EPS |
|---|---|---|---|---|---|
| 2025 | 460.48M +16.9% | 97.01M +21.5% | 599.53M +13.8% | 63.84M +0.9% | 2.77 +21.5% |
| 2024 | 394.00M +16.4% | 79.85M +21.3% | 526.78M +16.4% | 63.26M +2.0% | 2.28 +21.3% |
| 2023 | 338.44M | 65.83M | 452.74M | 62.00M | 1.88 |
Historical data sourced from Yahoo Finance and may differ from official audited financial reports.
Price Forecast
These forecasts are based on technical analysis and AI and do not constitute investment advice. Past performance does not guarantee future results.
News & Events
No news currently available for Avalon Pharma
Dividend History
Dividend data from Tadawul records. All amounts in SAR. Estimated yield calculated based on year-end price.
Ownership Structure
Data source: Yahoo FinanceLast updated: 2026-11-17
Risk Assessment
Risk Factors
Average True Range 3.1% of stock price
Trading volume near or above average
P/E ratio 27.8
Debt-to-equity ratio 0.41
ADX indicator at 20 — no clear direction
Moderate risk factors with some sector pressures
This assessment is automated based on quantitative data and does not constitute investment advice. Please consult a licensed financial advisor before making investment decisions.
FAQ
1 What is Avalon Pharma stock price today?
Avalon Pharma (4016) stock price today is 67.20 SAR, gaining by +1.82% compared to the previous session close. The 52-week price range is between 52.53 SAR and 69.47 SAR.
2 What is Avalon Pharma stock valuation?
The automated analysis signal for Avalon Pharma is "Buy" with 62% confidence. The P/E ratio is 27.8. The P/B ratio is 5.40.
3 Is Avalon Pharma Shariah-compliant?
Yes, Avalon Pharma (4016) is Shariah-compliant according to the latest lists approved by relevant Shariah authorities.
4 What are Avalon Pharma dividend distributions?
Avalon Pharma has a dividend yield of 2.36%, with an estimated annual dividend of 1.55 SAR per share.
5 What is Avalon Pharma weekly performance?
Avalon Pharma performance over different time periods: weekly change +8.30%, monthly +8.04%, and year-to-date +6.75%. The stock is currently trading with a volume of 235,658 shares.
6 What is the target level for Avalon Pharma?
According to automated analysis for Avalon Pharma: Short-term target (1-2 weeks): 69.22 SAR. Medium-term target (1-3 months): 72.58 SAR. Support level: 55.60 SAR. Resistance level: 68.40 SAR. Note: These are automated analytical levels and do not constitute investment advice.
Disclaimer
The information provided on this page is for educational and analytical purposes only and does not constitute investment advice or a recommendation to buy or sell. Past performance does not guarantee future results. All investments involve risk including loss of capital. Please consult a licensed financial advisor before making any investment decisions.
Automated analysis relies on historical data and technical indicators and may not reflect future market conditions.